The FDA has approved a new drug called Fintepla (fenfluramine) for seizures linked to two rare and severe forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. It is for patients 2 years of age and older. These conditions often do not respond well to existing treatments, so this approval offers a new oral option.
Fintepla is taken by mouth. The dose depends on the patient's weight and other medicines they take, especially stiripentol plus clobazam. Before starting Fintepla, patients must have an echocardiogram to check for heart valve problems or high blood pressure in the lungs. The maximum daily dose ranges from 17 mg to 26 mg.
This approval means more choices for families managing these challenging seizure disorders. However, it is not a cure. Patients and caregivers should talk to their doctor to see if Fintepla is right for them. The drug requires careful monitoring and dosing adjustments.
If you or a loved one has Dravet syndrome or Lennox-Gastaut syndrome, discuss this new option with your healthcare provider. They can help weigh the benefits and risks based on your specific situation.